نتائج البحث - Siqing Fu
- يعرض 1 - 20 نتائج من 90
- اذهب إلى الاصفحة التالية
-
1
Development of curcumin as an epigenetic agent حسب Siqing Fu, Razelle Kurzrock
منشور في 2010Revisão -
2
-
3
-
4
Prevalence of complementary medicine use in a phase 1 clinical trials program حسب Aung Naing, Saneese K. Stephen, Moshe Frenkel, Chandtip Chandhasin, David S. Hong, Xiudong Lei, Gerald S. Falchook, Jennifer J. Wheler, Siqing Fu, Razelle Kurzrock
منشور في 2011Artigo -
5
Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma حسب Aung Naing, Patricia LoRusso, Siqing Fu, David S. Hong, H. X. Chen, L. Austin Doyle, Alexandria T. Phan, Mouhammed Amir Habra, Razelle Kurzrock
منشور في 2013Artigo -
6
Validation of the royal marsden hospital prognostic score in patients treated in the phase I clinical trials program at the MD Anderson Cancer Center حسب Ignacio Garrido‐Laguna, Filip Janků, Christos Vaklavas, Gerald S. Falchook, Siqing Fu, David S. Hong, Aung Naing, Apostolia M. Tsimberidou, Sijin Wen, Razelle Kurzrock
منشور في 2011Artigo -
7
Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML حسب AB Deisseroth, Z. Zu, David F. Claxton, EG Hanania, Siqing Fu, Debra Ellerson, Laura Goldberg, Michael W. Thomas, Karen M. Janicek, WF Anderson
منشور في 1994Artigo -
8
PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers حسب Filip Janků, J. Jack Lee, Apostolia M. Tsimberidou, David S. Hong, Aung Naing, Gerald S. Falchook, Siqing Fu, Rajyalakshmi Luthra, Ignacio Garrido‐Laguna, Razelle Kurzrock
منشور في 2011Artigo -
9
Phase I Study of the Antiangiogenic Antibody Bevacizumab and the mTOR/Hypoxia-Inducible Factor Inhibitor Temsirolimus Combined with Liposomal Doxorubicin: Tolerance and Biological... حسب John W. Moroney, Siqing Fu, Stacy L. Moulder, Gerald S. Falchook, Thorunn Helgason, Charles Levenback, David S. Hong, Aung Naing, Jennifer J. Wheler, Razelle Kurzrock
منشور في 2012Artigo -
10
Insulin Growth Factor-Receptor (IGF-1R) Antibody Cixutumumab Combined with the mTOR Inhibitor Temsirolimus in Patients with Refractory Ewing's Sarcoma Family Tumors حسب Aung Naing, Patricia LoRusso, Siqing Fu, David S. Hong, Pete Anderson, Robert S. Benjamin, Joseph A. Ludwig, Helen X. Chen, L. Austin Doyle, Razelle Kurzrock
منشور في 2012Artigo -
11
Outcomes of Research Biopsies in Phase I Clinical Trials: The MD Anderson Cancer Center Experience حسب Hazem El‐Osta, David S. Hong, Jennifer J. Wheler, Siqing Fu, Aung Naing, Gerald S. Falchook, Marshall E. Hicks, Sijin Wen, Apostolia M. Tsimberidou, Razelle Kurzrock
منشور في 2011Artigo -
12
KRASness and PIK3CAness in Patients with Advanced Colorectal Cancer: Outcome after Treatment with Early-Phase Trials with Targeted Pathway Inhibitors حسب Ignacio Garrido‐Laguna, David S. Hong, Filip Janků, Ly M. Nguyen, Gerald S. Falchook, Siqing Fu, J. J. Wheler, Rajyalakshmi Luthra, Aung Naing, Xuemei Wang, Razelle Kurzrock
منشور في 2012Artigo -
13
Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment حسب Neeraj Gupta, Michael J. Hanley, Karthik Venkatakrishnan, Raymond P. Perez, Robin E. Norris, John Nemunaitis, Huyuan Yang, Mark G. Qian, Gerald S. Falchook, Richard Labotka, Siqing Fu
منشور في 2016Artigo -
14
Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies حسب Gerald S. Falchook, Siqing Fu, Aung Naing, David S. Hong, Wei Hu, Stacy L. Moulder, Jennifer J. Wheler, Anil K. Sood, Ernesto Bustinza-Linares, Kristin L. Parkhurst, Razelle Kurzrock
منشور في 2013Artigo -
15
Survival of 1,181 Patients in a Phase I Clinic: The MD Anderson Clinical Center for Targeted Therapy Experience حسب Jennifer J. Wheler, Apostolia M. Tsimberidou, David S. Hong, Aung Naing, Gerald S. Falchook, Sarina A. Piha‐Paul, Siqing Fu, Stacy L. Moulder, Bettzy Stephen, Sijin Wen, Razelle Kurzrock
منشور في 2012Artigo -
16
Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer حسب David S. Hong, Filip Janků, Aung Naing, Gerald S. Falchook, Sarina A. Piha‐Paul, Jennifer J. Wheler, Siqing Fu, Apostolia M. Tsimberidou, Michael Stecher, Prasant Mohanty, John Simard, Razelle Kurzrock
منشور في 2015Artigo -
17
Efficacy of pembrolizumab in patients with pituitary carcinoma: report of four cases from a phase II study حسب Nazanin Majd, Steven G. Waguespack, Filip Janků, Siqing Fu, Marta Penas‐Prado, Mingxuan Xu, Anas Alshawa, Carlos Kamiya-Matsuoka, Shaan M. Raza, Ian E. McCutcheon, Aung Naing
منشور في 2020Artigo -
18
Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience حسب Ming-Mo Hou, Xiaochun Liu, Jennifer J. Wheler, Aung Naing, David S. Hong, Robert L. Coleman, Apostolia M. Tsimberidou, Filip Janků, Ralph Zinner, Karen H. Lu, Razelle Kurzrock, Siqing Fu
منشور في 2014Artigo -
19
<i>PIK3CA</i> Mutation H1047R Is Associated with Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early-Phase Clinical Trials حسب Filip Janků, Jennifer J. Wheler, Aung Naing, Gerald S. Falchook, David S. Hong, Vanda M. Stepanek, Siqing Fu, Sarina A. Piha‐Paul, J. Jack Lee, Rajyalakshmi Luthra, Apostolia M. Tsimberidou, Razelle Kurzrock
منشور في 2012Artigo -
20
Mechanistic Basis for Overcoming Platinum Resistance Using Copper Chelating Agents حسب Liang Zheng, Yan Long, Wen-Bin Tsai, Siqing Fu, Razelle Kurzrock, Mihai Gagea-Iurascu, Fan Zhang, Helen H.W. Chen, Bryan T. Hennessy, Gordon B. Mills, Niramol Savaraj, Macus Tien Kuo
منشور في 2012Artigo
أدوات البحث:
موضوعات ذات صلة
Medicine
Internal medicine
Oncology
Cancer
Biology
Cancer research
Gastroenterology
Biochemistry
Clinical trial
Gene
Chemotherapy
Genetics
Adverse effect
Colorectal cancer
PI3K/AKT/mTOR pathway
Pharmacology
Chemistry
Immunotherapy
KRAS
Pathology
Confidence interval
Mutation
Physics
Breast cancer
Neutropenia
Ovarian cancer
Surgery
Signal transduction
Tolerability
Cisplatin